This is an open label phase 2 study to evaluate the combination of Vigil™ and nivolumab in
advanced or metastatic NSCLC that is progressive on or after one prior platinum-based
systemic therapy. Patients meeting study eligibility criteria will receive Vigil™ every 2
weeks (for a minimum of 4 and a maximum of 12 doses) and nivolumab every 2 weeks. The
combination of Vigil™ and nivolumab will demonstrate a higher objective response rate (ORR)
than the historical ORR of single agent nivolumab in patients with advanced NSCLC.